The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis

NCT01067326 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

22

Enrollment

OTHER

Sponsor class

Stopped Novartis ended all studies regarding Aliskiren.

Conditions

Endothelial Dysfunction

Interventions

DRUG: Aliskiren
DRUG: Placebo

Sponsor

Mayo Clinic

Collaborators

[object Object]
[object Object]
[object Object]